The safety of vedolizumab for ulcerative colitis and Crohn's disease

Colombel Jean-Frederic; Sands Bruce E.; Rutgeerts Paul; Sandborn William; Danese Silvio; DHaens Geert; Panaccione Remo; Loftus Edward V. Jr.; Sankoh Serap; Fox Irving; Parikh Asit; Milch Catherine; Abhyankar Brihad; Feagan Brian G.

首页> 外文期刊>Gut: Journal of the British Society of Gastroenterology >The safety of vedolizumab for ulcerative colitis and Crohn's disease

【24h】

The safety of vedolizumab for ulcerative colitis and Crohn's disease

机译：Vedolizuab为溃疡性结肠炎和克罗恩病的安全性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Objective Vedolizumab is a gut-selective antibody to alpha(4)beta(7) integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab.

机译：目标Vedolizumab是对α（4）β（7）整联蛋白的肠道选择性抗体，用于治疗溃疡性结肠炎（UC）和CrOhn疾病（CD）。我们报告了vedolizumab的安全综合摘要。

著录项

来源
《Gut: Journal of the British Society of Gastroenterology》 |2017年第5期|共13页
作者
Colombel Jean-Frederic; Sands Bruce E.; Rutgeerts Paul; Sandborn William; Danese Silvio; DHaens Geert; Panaccione Remo; Loftus Edward V. Jr.; Sankoh Serap; Fox Irving; Parikh Asit; Milch Catherine; Abhyankar Brihad; Feagan Brian G.;
展开▼
作者单位

Mt Sinai Hosp Icahn Sch Med Div Gastroenterol New York NY 10029 USA;

Mt Sinai Hosp Icahn Sch Med Div Gastroenterol New York NY 10029 USA;

Katholieke Univ Leuven Div Gastroenterol Leuven Belgium;

Univ Calif San Diego Div Gastroenterol La Jolla CA 92093 USA;

Ist Clin Humanitas Dept Gastroenterol Milan Italy;

Acad Med Ctr Dept Gastroenterol Amsterdam Netherlands;

Univ Calgary Dept Med Calgary AB Canada;

Mayo Clin Div Gastroenterol &

Hepatol Rochester MN USA;

Takeda Pharmaceut Int Co Cambridge MA USA;

Takeda Pharmaceut Int Co Cambridge MA USA;

Takeda Pharmaceut Int Co Cambridge MA USA;

Takeda Pharmaceut Int Co Cambridge MA USA;

Takeda Global Res &

Dev Ctr Europe Ltd London England;

Univ Western Ontario Dept Med Robarts Clin Trials Robarts Res Inst London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review [J] . Ulf Helwig, Michael Mross, Stefan Schubert, BMC Gastroenterology . 2020,第1期

机译：Vedolizumab和抗肿瘤坏死因子α治疗溃疡性结肠炎和克罗恩病患者的现实世界临床疗效和安全性：德国回顾性图表
2. The safety of vedolizumab for ulcerative colitis and Crohn's disease [J] . Colombel Jean-Frederic, Sands Bruce E., Rutgeerts Paul, Gut: Journal of the British Society of Gastroenterology . 2017,第5期

机译：Vedolizuab为溃疡性结肠炎和克罗恩病的安全性
3. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age [J] . Yajnik Vijay, Khan Nabeel, Dubinsky Marla, Advances in therapy. . 2017,第2期

机译：VEDOLIZUAB在溃疡性结肠炎和克罗恩病患者患者年龄分层的疗效和安全性
4. Analysis of integrated inflammatory bowel disease mouse models to assess their disease driving pathways and relevance for Crohn’s disease and Ulcerative colitis [C] . Weiwei Schultz, Calixte Monast, Mathias Hesse, IEEE International Conference on Bioinformatics and Biomedicine . 2018

机译：分析综合性炎症性肠病小鼠模型以评估其疾病驱动途径以及与克罗恩病和溃疡性结肠炎的相关性
5. Epigenetics of Crohn's Disease, Ulcerative Colitis, and Phenotypically Normal Individuals [D] . Phillips, Delisa L. 2017

机译：克罗恩病，溃疡性结肠炎和表型正常个体的表观遗传
6. Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario [O] . Fabiana Zingone, Brigida Barberio, Federico Compostella, 2020

机译：在真正的情景中Vedolizuab在克罗恩病和溃疡性结肠炎中的良好疗效和安全性
7. P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study [O] . B Bressler, A Yarur, U Kopylov, 2020

机译：P419临床效果和一线生物植物的临床效果和安全性作为溃疡性结肠炎和克罗恩病患者的单一疗法或联合治疗：演出研究的结果

The safety of vedolizumab for ulcerative colitis and Crohn's disease

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅